Antibody–Prodrug Conjugates with KSP Inhibitors and Legumain‐Mediated Metabolite Formation
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody–Prodrug Conjugates with KSP Inhibitors and Legumain‐Mediated Metabolite Formation
Authors
Keywords
-
Journal
CHEMISTRY-A EUROPEAN JOURNAL
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-03-14
DOI
10.1002/chem.201900441
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antibody-drug conjugates with pyrrole-based KSP inhibitors as novel payload class
- (2018) Hans-Georg Lerchen et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- MORAb-202, an antibody drug conjugate utilizing humanized anti-human FRa farletuzumab and the microtubule-targeting agent eribulin, has potent anti-tumor activity
- (2018) Xin Cheng et al. MOLECULAR CANCER THERAPEUTICS
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Structure and function of legumain in health and disease
- (2016) Elfriede Dall et al. BIOCHIMIE
- Abstract 1210: Preclinical pharmacology and repeated dose toxicity of the novel agonistic TWEAK receptor binding antibody BAY-356
- (2016) Sandra Berndt et al. CANCER RESEARCH
- Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
- (2016) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- High expression of the cysteine proteinase legumain in colorectal cancer – Implications for therapeutic targeting
- (2015) Mads H. Haugen et al. EUROPEAN JOURNAL OF CANCER
- Clinicopathologic significance of legumain overexpression in cancer: a systematic review and meta-analysis
- (2015) Ye Zhen et al. Scientific Reports
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
- (2014) John M. Lambert et al. JOURNAL OF MEDICINAL CHEMISTRY
- B7-H3-mediated tumor immunology: Friend or foe?
- (2013) Ling Wang et al. INTERNATIONAL JOURNAL OF CANCER
- Development of an Fc-Enhanced Anti-B7-H3 Monoclonal Antibody with Potent Antitumor Activity
- (2012) D. Loo et al. CLINICAL CANCER RESEARCH
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brentuximab Vedotin (SGN-35)
- (2011) J. Katz et al. CLINICAL CANCER RESEARCH
- Targeting Cell Surface Alpha(v)beta(3) Integrin Increases Therapeutic Efficacies of a Legumain Protease-Activated Auristatin Prodrug
- (2011) Yuan Liu et al. MOLECULAR PHARMACEUTICS
- Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma
- (2010) Jing Sun et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Legumain Protease-Activated Auristatin Prodrugs Suppress Tumor Growth and Metastasis without Toxicity
- (2010) Krishna Mohan Bajjuri et al. ChemMedChem
- A Novel Antitumor Prodrug Platform Designed to Be Cleaved by the Endoprotease Legumain
- (2009) Liron Stern et al. BIOCONJUGATE CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search